Cipla Limited (CIPLA) — Financial Results | 24 January 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Cipla Limited reported Q3 FY26 unaudited financial results for the quarter ended December 31, 2025. However, the filing document provided contains only regulatory notification disclosures and does not include actual financial data. The company's detailed results are available on its investor website and stock exchange platforms. Without access to the substantive financial statements, specific revenue, profit, and operational metrics cannot be extracted.

📄 View Original Announcement (PDF)

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day